Lavie Bio

Company Overview

Snapshot

Founded in January 2019, Lavie Bio operates with 11–50 employees and has raised a total of $37M across three funding rounds from two investors. The company was acquired by ICL in April 2025.

Business overview

Lavie Bio develops microbiome-based agricultural biological products to enhance food quality, health, and agricultural sustainability. The company utilizes proprietary computational predictive technologies to create biostimulants and biopesticides. Lavie Bio serves the agriculture industry, focusing on crops, and operates within the Agriculture & Food Technologies sector, specifically in Ag Tech, Sustainable Farming, and Genetics & Input.

Strategic signal

In April 2025, Lavie Bio was acquired by ICL. This acquisition signals a strategic move by ICL to integrate advanced microbiome-based solutions into its portfolio, validating Lavie Bio's technology and market potential within the agricultural biologicals sector.

Company Intelligence Q&A

What was a significant recent corporate development for Lavie Bio?

In April 2025, Lavie Bio was acquired by ICL, marking a major exit for the company and its investors.

Did Lavie Bio receive any grants recently?

In September 2024, Lavie Bio received a grant from the Israel Innovation Authority to advance the development of its 'MicroFermentor' technology.

What was Lavie Bio's collaboration with Corteva?

In February 2024, Lavie Bio successfully secured a $2.5M advance payment after meeting requirements for its licensing agreement with Corteva.

What strategic partnership did Lavie Bio announce in early 2024?

In February 2024, Lavie Bio announced a partnership with Syngenta to discover and develop a novel bio-insecticide.

When did Lavie Bio apply for regulatory approval for its bio-fungicide program?

In October 2022, Lavie Bio advanced its novel bio-fungicide program and applied to the U.S. EPA for regulatory approval.